Related Experiment Video
Updated: Jun 17, 2026
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
Published on: July 24, 2019
Challenging or less challenging oral diadochokinetic tasks-what works best in Huntington disease? A cross-sectional
Wiebke Hannemann1, Lukas Stahuber1, Tomas Kouba2
1Department of Neurology, Huntington Center Ulm (HCU), Ulm University, Oberer Eselsberg 45, 89081, Ulm, Germany.
Background:
In Huntington disease (HD), speech alterations are common and may emerge before onset of chorea. Slow and irregular motion rates, i.e. altered oral diadochokinesis (oDDK), are a distinctive feature. This study investigated oDDK using alternating (AMR) and sequential motion rate (SMR) tasks in manifest HD and explored the impact of antidopaminergic medications (ADM).
Methods:
Speech samples were acquired from 30 healthy controls (14 men; 27-78 years¸ age- and gender-matched to HD subjects) and 35 individuals with early-to-moderate HD (18 men; 22-76 years) phenotyped using standardized scales (UHDRS'99) and MR imaging to estimate disease severity. Acoustic analysis was used to quantify rate and regularity of oDDK. In an exploratory subgroup analysis, the impact of ADMs on oDKK was explored by comparing patients with and without ADMs (HD-ADM: n = 16; 8 men; 22-76 years; HD-nADM; n = 19; 10 men; 28-61 years).
Results:
HD patients were slower and more irregular in AMR and SMR tasks (p < 0.001) compared to controls. Analyses using area under the receiver-operating characteristic curve (AUC) showed the best characteristics for AMR (AUC = 95.0%). oDDK parameters correlated with measures of motor, cognitive and functional impairment and striatal atrophy. Patients on ADMs showed slower motion rates in both tasks (AMR p = 0.021; SMR p = 0.026), but unchanged regularity.
Conclusions:
Decreased AMR performance alone captured early motor impairment accurately, reflects disease severity and is ADM-sensitive. Therefore, objective acoustic analysis of AMR performance is a simple measure which may serve as read-out to monitor disease progression, e.g. in clinical trials.
